NEW YORK, April 26 (GenomeWeb News) - Becton Dickinson today said that total revenues for its fiscal second quarter increased 6.1 percent as R&D spending surged 96 percent and profits declined.
Total receipts for the three months ended March 31 increased to $1.45 billion from $1.37 billion year over year. Revenue from the BD Biosciences unit grew 7.7 percent to $219 million year over year, the second-highest growth this period from among the company's three divisions.
R&D spending increased to $129 million from $66 million in the year-ago period, the company said.
Profits declined to $154 million, or $.63 per share, from $188.2 million, or $.74 per share, year over year.